Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cephalon Must Report Payments To Physicians In Settlement Of Off-Label Charges

Executive Summary

Cephalon is to become the third pharmaceutical company to disclose its payments to physicians. While Lilly and Merck recently volunteered to do so, Cephalon's disclosure is mandated under a settlement agreement with the U.S. Department of Justice to resolve charges that it promoted off-label use of three drugs

You may also be interested in...

Gottlieb Advances, But FDA's Future Seems Increasingly Partisan

Senate committee votes to send the FDA Commissioner nominee to the Senate floor, but with only two Democratic votes.

Cephalon's Double Trouble: DoJ Probes Treanda Marketing, Clinical Trial Data

The inquiry comes three years after the company settled a government investigation of off-label marketing of three other drugs.

Cephalon Is First Company To Release Physician Payments Under Consent Decree

The company, which does not cap its physician payments, paid 937 doctors for consulting and speaking services in 2009; its top-paid physician earned $149,900.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts